Umang Swami, MD, MSCI, FASCO

Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel bit.ly/3U1d88k @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10)

Congrats @ggebraelmd superstar from @UofUInternalMed for another new paper @JAMANetworkOpen! Remarkable trajectory as an IM resident w extensive clinical research portfolio in #GU onc. Wishing him the best of luck in the #hemeonc fellowship match! @neerajaiims @carolinemilneMD

Real-world mCRPC data (2021–25; n=5,096): marked attrition: only ~53% reach 2L & ~26% 3L. ARPIs dominate early; taxanes later (but only 43% ever receive taxane); Lu-177 uptake rising; Urgent need to optimize treatment and expand access bit.ly/4xa5uew @OncoAlert @PCFnews

Huge congratulations to my mentor and friend @neerajaiims on his election to the @ASCO Nominating Committee. A true leader whose humility, vision, and mentorship continue to inspire so many. @OncoAlert brnw.ch/21wYvzE

Another razor-sharp panel discussion @Uromigos summarizing recent/ongoing trials and approaches in metastatic/refractory RCC - biomarkers (OPTIC/KIM1), VEGF/PD1 and other bispecifics, microbiome, CAR-T #UromigosLive @OncoAlert @urotoday